Voyager Therapeutics
VYGR
101 hedge funds and large institutions have $130M invested in Voyager Therapeutics in 2021 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 31 increasing their positions, 31 reducing their positions, and 17 closing their positions.
12% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 17
0% more funds holding
Funds holding: 101 → 101 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 31
2.22% less ownership
Funds ownership: 73.9% → 71.68% (-2.2%)
34% less capital invested
Capital invested by funds: $198M → $130M (-$68.1M)
82% less call options, than puts
Call options by funds: $300K | Put options by funds: $1.62M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$5.02M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$3.09M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.66M |
| 4 |
Two Sigma Investments
New York
|
+$2.23M |
| 5 |
AC
Armistice Capital
New York
|
+$2.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$18.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$4.03M |
| 3 |
Renaissance Technologies
New York
|
-$2.76M |
| 4 |
Morgan Stanley
New York
|
-$1.73M |
| 5 |
Goldman Sachs
New York
|
-$1.57M |
VYGR Hedge Fund Activity: Q1 2021 in Review
101 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q1 2021, worth a combined $130M — down 34% from $198M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new VYGR positions and 17 closed out — a net gain of 2 holders — while 31 added to existing stakes and 31 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $5.02M. The largest seller was Bellevue Group, cutting an estimated $18.3M.
- 101 institutional investors held Voyager Therapeutics (VYGR) as of Q1 2021, unchanged from Q4 2020.
- Funds reported $130M of Voyager Therapeutics stock for Q1 2021, down 34% quarter-over-quarter.
- 19 funds opened new Voyager Therapeutics positions in Q1 2021 and 17 closed out, a net change of +2 holders.
- The largest Voyager Therapeutics buyer in Q1 2021 was JP Morgan Chase, an estimated $5.02M added.
- The largest Voyager Therapeutics seller in Q1 2021 was Bellevue Group, an estimated $18.3M sold.
Based on aggregated 13F filings for Q1 2021.